Springer Nature
Browse
12913_2017_1995_MOESM1_ESM.docx (26.79 kB)

Additional file 1: of Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences

Download (26.79 kB)
journal contribution
posted on 2017-01-23, 05:00 authored by Tereza Lanitis, Robert Leipold, Melissa Hamilton, Dale Rublee, Peter Quon, Chantelle Browne, Alexander Cohen
The objective of this appendix is to provide additional technical documentation to the manuscript detailing the model calculations and data used to calculate the transition matrix in the model. (DOCX 26 kb)

Funding

Bristol-Myers Squibb

History

Usage metrics

    BMC Health Services Research

    Categories

    Keywords

    Venous thromboembolismApixabanVitamin K antagonistsCost-effectiveness

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC